EW Healthcare Partners Announces Acquisition of Germfree Laboratories, Inc.
18 oct. 2022 12h46 HE
|
EW Healthcare Partners
NEW YORK and ORMAND BEACH, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- EW Healthcare Partners announced today that it has acquired Germfree Laboratories, Inc., a leading U.S. manufacturer of turnkey,...
EW Healthcare Partners Acquires Germfree Laboratories, Inc.
18 oct. 2022 12h16 HE
|
EW Healthcare Partners
NEW YORK and ORMAND BEACH, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- EW Healthcare Partners announced today that it has acquired Germfree Laboratories, Inc., a leading U.S. manufacturer of turnkey,...
Helena Strigård appointed as new CEO of rapidly expanding NorthX Biologics
20 sept. 2022 01h00 HE
|
NorthX Biologics Matfors AB
MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Board of NorthX Biologics ("NorthX") has appointed Helena Strigård as the new CEO. She joins NorthX from her role as Director General for the...
Helena Strigård ny vd för snabbt expanderande NorthX Biologics
20 sept. 2022 01h00 HE
|
NorthX Biologics Matfors AB
MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- NorthX Biologics (“NorthX”) styrelse har utsett Helena Strigård till ny vd. Hon kommer närmast från rollen som vd för branschorganisationen...
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
12 juin 2022 05h30 HE
|
Novartis Pharma AG
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than...
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
27 mai 2022 18h58 HE
|
Novartis Pharma AG
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah...
AGC Biologics Invests in New Viral Vector Suspension Capabilities at U.S. Cell & Gene Hub
17 mai 2022 22h03 HE
|
AGC Biologics
SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector...
Cell and Gene Therapy Market Size, Growth, Trends [2022] | Global Industry Share, Key Players, Recent Developments, Type & Application, Challenges & Restraints, Revenue, Stakeholders and Forecast Research | Market Reports World
09 mai 2022 01h36 HE
|
Market Reports World
Pune, May 09, 2022 (GLOBE NEWSWIRE) -- Global Cell and Gene Therapy Market Size 2022 research report provides an in-depth analysis of market size, share, growth, trends, and forecast. The Cell and...
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
25 mars 2022 08h03 HE
|
Novartis Pharma AG
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial...
Almac Pharma Services Expands Its Unique Ultra-Low Temperature Solutions for Advanced Therapy Medicinal Products
14 mars 2022 12h31 HE
|
Almac Group
CRAIGAVON, Northern Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial...